1. The pathogenesis of traumatic coagulopathy.
Cap A, Hunt BJ.

2. The current place of tranexamic acid in the management of bleeding.
Hunt BJ.

3. Blood - the most important humour?*
Bailey CR, Klein AA, Hunt BJ.

Cap A, Hunt B.

5. Thrombosis: A major contributor to global disease burden.
ISTH Steering Committee for World Thrombosis Day; ISTH Steering Committee for World Thrombosis Day (Hunt).

6. Thrombosis: a major contributor to global disease burden.

7. Thrombosis: a major contributor to global disease burden.

8. Thrombosis: a major contributor to the global disease burden.
ISTH Steering Committee for World Thrombosis Day (Hunt).

ISTH Steering Committee for World Thrombosis Day; ISTH Steering Committee for World Thrombosis Day.(Hunt)

10. New oral anticoagulants in the management of venous thromboembolism: a major advance?
Sciascia S, Hunt BJ.


21. Excellence, quality and limitations of the NICE venous thromboembolism score tool: how can it be improved? **Cohen AT**, Granziera S.
22. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.

23. Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy.

24. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.

25. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction).

26. A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study.

27. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer.

28. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.

30. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.


54. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
Rea CJ, Foley JH, Bevan DH, Sørensen B.

55. A national survey of immunosuppression strategies for acquired haemophilia A.


58. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Rangarajan S¹, Jiménez-Yuste V, Santagostino E.

59. Rationale for individualizing haemophilia care.

60. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
Oldenburg J¹, Austin SK, Kessler CM.

61. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.
Lentz SR¹, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN; adept™2 investigators. (Austin)

62. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study.

63. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
64. Laboratory testing for the lupus anticoagulant. Approved guideline – first edition. Ledford-Kraemer MR (Chair), Moore GW (Vice-Chair), Bottenus R, Daniele C, de Groot PG, Exner T, Favaloro EJ, Moffat KA, Nichols WL. CLSI document H60-A. Clinical and Laboratory Standards Institute Wayne, PA, USA April 2014


71. Ongoing risk of thrombosis with factor XI concentrate: five years experience in two centres Batty, Paul; Honke, Anja; Bowles, Louise; Hart, Dan; Pasi, John; Uprichard, James; Austin, Steve Haemophilia, in press.


